Sanaria Inc.

This study tests a new malaria vaccine in 180 healthy adults aged 18-50 in Burkina Faso. The vaccine uses weakened malaria parasites that stop growing in the liver, so they cannot cause blood-stage infection. Participants receive either one or two doses of the vaccine or a placeb…

This early-stage trial tests a new malaria vaccine (PfSPZ-LARC2) in 58 healthy adults who have never had malaria. The vaccine uses weakened malaria parasites that stop growing in the liver and cannot cause blood infection. Researchers will check if it is safe and if it protects a…